Skye Bioscience SKYE
NASDAQ SKYE
$1.07 -0.03 (-2.29%)
At close: Nov 16, 2026 · 4:00 PM EST

Skye Bioscience (SKYE) Depreciation & Amortization - Total (2013)

Updated

Skye Bioscience (SKYE) recorded Depreciation & Amortization - Total of $3,854 in Q3 2013.

Analysis

Skye Bioscience (SKYE) Depreciation & Amortization - Total (2013) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Dep. & Amort. (Tot) (Qtr)
1 Eli Lilly 1,276.89 Bn 1,250.50 Bn 20.46 Bn -
2 Johnson & Johnson 681.31 Bn 601.18 Bn 17.30 Bn -
3 AbbVie 520.63 Bn 488.64 Bn 13.12 Bn -
4 Merck 357.22 Bn 320.16 Bn 13.19 Bn -
5 Novartis Ag 310.90 Bn 284.14 Bn - -
6 Astrazeneca 285.12 Bn 258.77 Bn 13.26 Bn -
7 Amgen 250.23 Bn 201.89 Bn 7.58 Bn -
8 Gilead Sciences 207.56 Bn 182.67 Bn 6.73 Bn -
9 Pfizer 164.42 Bn 111.77 Bn 12.56 Bn -
10 Skye Bioscience 5.38 Mn -52.34 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jul 31, 2013 3,854.00
API Access

Skye Bioscience Depreciation & Amortization - Total API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=depreciation-and-amortization-total&ticker=SKYE&period=max&api_key=YOUR_API_KEY